Press Release: Santhera Completes Capital Increase to Create Shares for IRIS

Pratteln, Switzerland, April 8, 2020 -- Santhera Pharmaceuticals (SIX:

SANN) announces that the number of its shares recorded in the commercial

register has been increased from 11,164,563 shares by 1,150,000 shares

to 12,314,563 shares.

On April 8, 2020, 1,150,000 shares were issued out of the existing

authorized capital as treasury shares. Santhera expects to use these

shares under the equity-linked financing provided by IRIS announced

earlier today.

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical

company focused on the development and commercialization of innovative

medicines for rare neuromuscular and pulmonary diseases with high unmet

medical need. Santhera is building a Duchenne muscular dystrophy (DMD)

product portfolio to treat patients irrespective of causative mutations,

disease stage or age. A marketing authorization application for

Puldysa(R) (idebenone) is currently under review by the European

Medicines Agency. Santhera has an option to license vamorolone, a

first-in-class anti-inflammatory drug candidate with novel mode of

action, currently investigated in a pivotal study in patients with DMD

to replace standard corticosteroids. The clinical stage pipeline also

includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other

neutrophilic pulmonary diseases, as well as omigapil and an exploratory

gene therapy approach targeting congenital muscular dystrophies.

Santhera out-licensed ex-North American rights to its first approved

product, Raxone(R) (idebenone), for the treatment of Leber's hereditary

optic neuropathy (LHON) to Chiesi Group. For further information, please

visit

https://www.globenewswire.com/Tracker?data=MXuwg4SKxpFBh8BcV2gbFH74xiPoaDl5maWqRg-gTnsWELAfAhapk06hHsdhYfBld37iuWICnR8uyUHxzwkecw==

www.santhera.com.

Raxone(R) and Puldysa(R) are trademarks of Santhera Pharmaceuticals.

For further information please contact:

https://www.globenewswire.com/Tracker?data=IGq8Hgbi6NrisFbWIG6jEKC-uBRMkYi6eKbaedz1jgm4oHsZknEZMNrK4koQ-wta5-YJmfp5Sa3-mNXvyF24AlytFOEulM_RHm1GDiLqa2UIrA7VPiUzjIJO2OgeiJVY

public-relations@santhera.com or

Eva Kalias, Head External Communications

Phone: +41 79 875 27 80

eva.kalias@santhera.com

Disclaimer / Forward-looking statements

This communication is not intended to constitute an offer or

solicitation to purchase or invest in any securities of Santhera

Pharmaceuticals Holding AG (the "Company"). The securities of the

Company to which this communication relates have not been and will not

be registered under the U.S. Securities Act of 1933, as amended, and may

not be offered or sold in or into the United States. No action has been

taken by the Company that is intended to permit a public offering of the

securities to which this communication relates in any jurisdiction.

This document may contain certain forward-looking statements relating to

the Company and its business. Such statements involve certain risks,

uncertainties and other factors which could cause the actual results,

financial condition, performance or achievements of the Company to be

materially different from those expressed or implied by such statements.

Readers should therefore not place undue reliance on these statements,

particularly not in connection with any contract or investment decision.

The Company disclaims any obligation to update any such forward-looking

statements.

# # #

Attachment

-- 2020 04 08_Iris cap inr_e_final

https://ml-eu.globenewswire.com/Resource/Download/b5ea7ffb-8d51-4bec-8a88-54bbcefe2d03

(END) Dow Jones Newswires

April 08, 2020 16:00 ET (20:00 GMT)